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Abstract
Background: Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described
that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study
was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions.
Methodology/Principal Findings: This study was conducted in 697 habitants from 4 Colombian departments: Amazonas,
Choco ´, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual
aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs
and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the
geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p=0.033)
and anti-HBc (p,0.001) were more frequent in Amazonas and Magdalena departments. Isolated anti-HBs (a marker of
previous vaccination) frequencies were: Choco ´ (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andre ´s (15.33%) -
p,0.001. Prevalence of anti-HBc increased with age; HBsAg varied from 1.97 to 8.39% (p=0.033). Amazonas department
showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andre ´s Island
(0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas
region and 1 from them Magdalena department.
Conclusions/Significance: In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency
levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena
departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are
reinforced by these results.
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Introduction
Around two billion people worldwide have been infected by
hepatitis B virus (HBV) and approximately 350 million people are
chronic carriers. Every year about one million deaths are caused
by chronic HBV infection [1]. Approximately 400.000 new cases
are estimated to occur in Latin America each year and 10 to 70%
of them may evolve to hepatocellular carcinoma [2]. Considering
the HBV infection epidemiology throughout different geograph-
ical zones, the world is divided in high, intermediate and low
endemicity areas, corresponding to infection rates higher than 8%,
2 to 8% and lower than 2%, respectively [3].
The routes of HBV transmission in South and Central America
are highly variable. The highest prevalence was reported in 20 to
40 years old age group, and adult horizontal transmission is the
most common route of infection [4]. Furthermore, vertical and
childhood horizontal transmission are also important in areas of
high endemicity such as the Amazon Basin [5,6].
HBV strains have distinct geographical distribution that are
classified in nine genotypes (A to I) based on genome diversity and
some of them are further classified in subgenotypes [7]. In
Colombia, subgenotype F3 is the most common subgenotype
among the HBV infected patients, but it was also reported an
important frequency of genotypes E, A2, G and F1b among HBV
chronic patients [8,9].
Hepatitis D virus (HDV) is a subviral agent that requires a
preexisting or concurrent infection with HBV [10]. HDV genome
is a 1672 to 1697 nucleotides circular single-strand RNA of with
extensive intramolecular complementarity [11,12]. Compared
with infection with HBV alone, HDV coinfection with HBV is
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infection and HDV superinfection in individuals with chronic
HBV infection can lead to more severe progressive chronic liver
disease [10].
HDV is classified in eight different genotypes: genotype 1 is the
most frequent and found in Europe, Middle East, North America
and North Africa [13–15]; genotype 2 is seen in the Far East;
genotype 3wasreported inthe AmazonianregionofSouthAmerica
[16,17]; genotype 4 was isolated in Taiwan and Japan [18–20]; and
genotypes 5 to 8 have been identified in Africans [21]. HDV is
distributed worldwide with more than 24% of HBV carriers with
HDV markers present in Africa, Southwest Asia and in the
Mediterranean basin. In the United States, HDV prevalence is
lower, ranging from 1 to 10% [22]. In Colombia, few reports are
available on HDV prevalence, mainly showing its association to
fulminant hepatitis outbreaks in departments with intermediate or
high HBV endemicity, particularly in the Amazonas department
where high HDV antibodies prevalence rates have been found
among children younger than 4 years old [23].
Hepatitis C virus (HCV) infection is a public health problem
throughout the world infecting around 3% of the world
population. HCV is classified in six major genotypes and more
than 70 subtypes [24,25]. It is an enveloped, single stranded
positive sense RNA virus with a 50 nm diameter viral particle,
classified in Hepacivirus genus of the Flaviviridae family [26].
Countries with the highest reported prevalence rates are located
in Africa and Asia; while lower prevalence areas include North
America, North and West Europe, and Australia [27]. In Latin
America, HCV overall prevalence is 1.23% [4]. However, the
HCV antibody in blood donors in Latin America varies from 0.2%
–0.5% in Chile to 1.7% –3.4% in northeast of Brazil [4,28,29].
The main risk factors are unsafe injection techniques and blood
transfusions [29]. Mandatory screening for HCV infection was
gradually adopted in Latin America during the 1990s, leading to a
currently decreased blood transmission in most South American
countries [4,29]. One study carried out in Colombia during 2005
showed a prevalence of 9% of HCV among multi-transfused
patients [30]. The distribution of HCV genotypes in Colombia
showed that subtype 1b is the most prevalent and that HCV
emerged in Bogota ´ around 60 years ago [31].
Since in Colombia there are few epidemiologic studies about the
hepatitis virus, the aim of this study was to determine the
frequency of serological markers for viral hepatitis B, C and D
(delta) in four regions in Colombia and to analyze the risk factors
associated with viral transmission in these populations.
Methods
Study population
This study was conducted in 697 habitants with ages varying
from 12 to 72 years old from the rural and urban areas of four
departments in Colombia: Amazonas (n=184), Choco ´ (n=138),
Magdalena (n=218) and San Andres Islands (n=156) (Figure 1).
Epidemiological data were obtained from an interview applied to
each individual aiming to evaluate risk factors related to HBV,
HCV or HDV infections. The Ethical Committees of the
Pontificia Universidad Javeriana, Bogota ´, Colombia and the
University of Sa ˜o Paulo Medical School, Sa ˜o Paulo, Brazil,
approved this protocol. All patients have signed an informed
consent form before joining the study.
Sampling was carried out for each department during the span
of a week. The individuals were summoned in the public health
laboratory from each region. Different risk groups were evaluated
in this study. In the Amazonas department, sampling was
performed in the area of the Amazon River, involving Amerindian
populations originating from four different ethnic groups (Ticuna,
Huitoto, Huinane, and Yagua). In Choco ´ department and San
Andres Islands, sampling included female sex workers, doctors and
nurses. In Magdalena department, it included medical workers
and ‘‘desplazados’’ populations (i.e., people that were obliged to
leave their homes due to the civil war).
Serological tests
All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-
HCV markers. Samples that were positive to for HBsAg and/or
anti-HBc were tested to anti-HDV. These assays were performed
using commercial available ELISA kits (DiaSorin, Italy).
Statistical analyses
Statistical analyses were performed using Minitab Software v.
15. The x
2 test for linear trend (a=0.05) was used to examine the
distribution of HBV, HCV and HDV markers according to age
group, sex, and geographical origin. Results were considered
statistically significant when p,0.05.
Results
The results for all serological markers tested in the samples and
for the statistical analysis according to three analyzed variables
(sex, age group and geographical origin of the samples) are shown
in Table 1.
Hepatitis B virus markers (HBsAg, anti-HBc and anti-HBs)
In spite of the higher frequency of anti-HBc and anti-HBs
positive cases when comparing males to females patients, these
differences were not statistically significant (p=0.051 and
p=0.089, respectively). Anti-HBc (p,0.001) frequency increased
with age, from the 11–15 years old group to the .51 years old
group. Anti-HBs (p=0.026) frequency was also different in the
several age groups and was higher in the 46–50 and .51 years old
groups. HBsAg frequency was not different according to sex and
age (p=0.378 and p=0.502, respectively).
Amazonas and Magdalena departments showed the highest
frequency for all HBV markers while San Andres Islands and
Choco ´ showed a low frequency for them. The differences for
HBsAg (p=0.033), anti-HBc (p,0.001) and anti-HBs (p,0.001)
frequencies in the various geographical origins of the samples were
statistically significant.
Concerning the geographical origin of the samples, the three
HBV markers showed a statistically significant difference. HBsAg
(p=0.033) and anti-HBc (p,0.001) were more frequent in
Amazonas and Magdalena departments and less frequent in San
Andre ´s Islands and Choco ´. For anti-HBs (p,0.001), the highest
and lowest frequencies were also observed in Amazonas
department and San Andre ´s Islands, respectively, but Choco ´
department showed the second highest frequency.
Another analysis was carried out to verify the frequency of
isolated anti-HBs as a marker of previous vaccination. Its
frequency by geographical origin of the samples was: Choco ´
(53.26%), Amazonas (32.88%), Magdalena (17.0%) and San
Andre ´s (15.33%) - p,0.001. Isolated anti-HBs distribution was
not different according to sex and age (p=0.089 and p=0.860,
respectively).
Hepatitis C marker (anti-HCV)
Amazonas department showed the highest frequency for anti-
HCV marker (5.68%). The lowest frequency was found in San
Andre ´s Island (0.66%) and intermediate levels were found in the
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significant (p=0.107). Considering age groups, the higher
frequency for anti-HCV was found from 26 to 30 (7.22%) years
old, but it was not statistically significant (p=0.259). Geographical
origin of samples did not show statistically significant difference
considering the presence of anti-HCV in the population
(p=0.107).
Hepatitis Delta marker (anti-HDV)
One-hundred seventy three anti-HBc positive and/or HBsAg-
positive samples were screened for anti-HDV. Nine (5.20%)
samples (from 3 males and 6 females) were positive for this marker.
Eight of these samples were from the Amazonas region and one
sample came from Magdalena department. Anti-HDV positive
patients ranged from 21 to 67 years old. No statistically significant
differences were found for anti-HDV distribution and sex
(p=0.949). For age group and geographical origin of samples, it
was not possible to carry out a statistical analysis due to the small
number of positive samples.
Discussion
In Colombia, there are a few studies about hepatitis
epidemiology. This is the first currently study reporting HBV,
HCV and HDV serological profiles in these four departments
(Amazonas, Choco ´, Magdalena and San Andre ´s Islands).
Figure 1. Geographic localization of the four places from where samples were collected in Colombia. The capital of each department is
in red (N).
doi:10.1371/journal.pone.0018888.g001
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28.43% and 5.66%, respectively. These rates include Colombia as
an intermediate endemicity region in at least these four regions
that we have analyzed. HBsAg positivity rates ranged from 1.97%
in San Andre ´s Islands to 8.39% in Magdalena department, slightly
surpassing the intermediate endemicity rates (2 to 8%) in this last
department.
Serological markers for HBV infection have been previously
found to range from 25 to 83% among Amazonian peoples in
Bolivia, Brazil, Peru and Venezuela [32,33]. In a study performed
between 1977 and 1989, overall HBsAg seroprevalence rate was
4.7% in Colombia [34].
In a previous paper analyzing the different Colombian regions,
HBsAg prevalence was 7.1%, 3.5% and 2.8% in the Central region,
in the Pacific zone and in the Eastern region, respectively [35]. In
the present paper, we have analyzed Choco ´, in the Pacific region,
and we have found a HBV intermediate prevalence of 3.7% of the
studied population, very close to the previously reported.
In another study carried out in 1975 involving native Choco ´
people who lived in the Darien forest, it was reported a higher
exposure to HBV: 42% anti-HBs positive but only 1.2% HBsAg
positive [36]. The prevalence of HBV markers among these native
Choco ´ people is lower than that found in the Choco ´ population
studied in the present paper as well as that found in other native
people who live in the Amazon department, as shown below. This
difference might be related to the higher sensitivity of the
methodology applied nowadays.
Western Amazonas basin is reported as one region with the
highest rates of hepatitis B infection in the world as more than
80% of people living in some rural areas have been infected with
HBV and more than 8% carry HBsAg [4,37,38]. In the present
paper, we are reporting 7.95% HBsAg positivity among the
studied population from Amazonas department, confirming that
HBV infection remains a problem in this region.
Near the capital of Magdalena department, Santa Marta city, in
northern Colombia, recurrent epidemics of severe hepatitis have
been reported over many years and have acquired the name of
‘‘Santa Marta hepatitis’’. This hepatitis was described in 1930s
[39] as a severe icteric illness with mortality as high as 10% [40].
HBsAg frequency found in Magdalena department in this study
was 8.39%, the highest found among the 4 departments analyzed.
Previous studies carried during the 809s found HBsAg levels higher
in studies of the populations affected with ‘‘Santa Marta Hepatitis’’
[34]. The present study could not study the population of Sierra
Nevada de Santa Marta where these epidemics have been
described but the finding of higher levels of HBV endemicity in
this area shows that it is remains a public health problem in this
area.
To our knowledge, previous data on the frequency of hepatitis
viruses markers at San Andre ´s Islands have not been published
before. These islands showed the lowest prevalence for all HBV
and HCV markers among the four studied regions. HDV infection
was not detected.
Anti-HBc positivity increased in older age groups. This finding
agrees with the known role of sexual transmission in HBV
spreading. As we did not have studied any children with less than
12 years old in this study, we cannot evaluate the role of vertical
transmission for hepatitis infection in this population. Anti-HBs
Table 1. Results for each HBV, HDV and HCV serology marker evaluated in the Colombian population (.11 years old).
Variables
HBsAg
Positives/n (%)
anti-HBc
Positives/n (%)
anti-HBs
Positives/n (%)
Isolated anti-HBs
Positives/n (%)
anti-HDV
Positives n (%)
anti-HCV
Positives/n (%)
Sex
Male group 7/163 (4.29%) 56/163 (34.36%) 73/149 (48.99%) 33/96 (34.38%) 3/56 (5.36%) 6/163 (3.68%)
Female group 28/455 (6.15%) 120/456 (26.32%) 175/427 (40.98%) 78/306 (25.49%) 6/117 (5.13%) 16/456 (3.51%)
p 0.378 0.051 0.089 0.089 0.949 0.919
Age group (years)
11–15 1/32(3.13%) 0/32(0.00%) 6/30 (20.00%) 6/30 (20.00%) no samples 0/32(0.00%)
16–20 5/58(8.62%) 7/58 (12.07%) 19/54 (35.19%) 11/45 (24.44%) 0/7 (0.00%) 1/58 (1.72%)
21–25 8/130(6.15%) 25/130 (19.23%) 43/116 (37.07%) 25/94 (26.60%) 1/22 (4.55%) 6/130 (4.62%)
26–30 8/97(8.25%) 26/97 (26.80%) 44/94 (46.81%) 23/66 (34.85%) 0/23 (0.00%) 7/97 (7.22%)
31–35 4/69(5.80%) 20/69 (28.99%) 29/64 (45.31%) 12/45 (26.67%) 1/22 (4.55%) 2/69 (2.90%)
36–40 0/61(0.00%) 20/62 (32.26%) 26/58 (44.83%) 11/38 (28.95%) 1/20 (5.00%) 0/62(0.00%)
41–45 2/55(3.64%) 19/55 (34.55%) 21/52 (40.38%) 7/33 (21.21%) 3/20 (15.0%) 2/55 (3.64%)
46–50 3/35(8.57%) 17/35 (48.57%) 19/33 (57.58%) 5/16 (31.25%) 1/18 (5.56%) 0/35(0.00%)
.51 4/81(4.94%) 42/81 (51.85%) 41/75 (54.67%) 11/35 (31.43) 2/41 (4.88%) 4/81 (4.94%)
p 0.502 ,0.001 0.026 0.860 * 0.259
Geographical Origin
Amazonas 14/176 (7.95%) 96/176 (54.55%) 105/168 (62.50%) 24/73 (32.88%) 8/97 (8.25%) 10/176 (5.68%)
Choco ´ 5/135 (3.70%) 25/136 (18.38%) 67/115 (58.26%) 49/92 (53.26%) 0/27 (0.00%) 5/136 (3.68%)
San Andre ´s Island 3/152 (1.97%) 6/152 (3.95%) 25/143 (17.48%) 21/137 (15.33%) 0/9 (0.00%) 1/152 (0.66%)
Magdalena 13/155 (8.39%) 49/155 (31.61%) 51/150 (34.00%) 17/100 (17.00%) 1/40 (2.50%) 6/155 (3.87%)
p 0.033 ,0.001 ,0.001 ,0.001 * 0.107
Total 35/618 (5.66%) 176/619 (28.43%) 248/576 (43.06%) 111/402 (27.61%) 9/173 (5.20%) 22/619 (3.55%)
*p value was not calculated due to the small number of positive samples.
doi:10.1371/journal.pone.0018888.t001
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HBsAg positivity did not showed a statistically significant
difference with age as some age groups showed particularly lower
levels of HBsAg detection (especially the 36 to 40 years old age
group).
Cuba, Colombia and Brazil were the first countries in Latin
America that introduced universal HBV vaccination in the early
1990s [41]. Isolated anti-HBs (i.e., immunized after vaccination)
individuals constitute only 17.96% (n=111) of the studied
population (n=618). Considering only the susceptible individuals
(n=402), i.e., anti-HBc and HBsAg seronegatives but anti-HBs
seropositives, only 27.61% of them were protected against HBV
infection. Isolated anti-HBs was detected in more than half and in
about one third of susceptible individuals in Choco ´ and Amazonas
departments, respectively. In San Andre ´s Islands and Magdalena
departments, isolated anti-HBs levels are only 15.33 and 17.00%,
respectively. It is noteworthy that the highest HBsAg positive rate
was detected in Magdalena department.
In 2002, it was reported a HBV vaccine coverage in Choco ´ about
26.2% [42]. In Choco ´ department, we found that 53.26%
individuals with isolated anti-HBs, reflecting previous HBV
vaccination, what would explain the HBsAg frequency found. At
San Andre ´s Islands, we found a low frequency of isolated anti-HBs
(15.3%) but also a lower frequency of HBV infection markers.
Isolated anti-HBs frequency was 32.88% in Amazonas department.
These results show that HBV vaccination must be reinforced in
Colombia as an effective health program for this population to
prevent new hepatitis B cases. This is an important public health
problem involving the costs for the implementation of widespread
efficient vaccination programs in large regions inside scarcely
inhabited areas where the populations are spread in small villages
located in the middle of the equatorial rain forest. Furthermore,
such program might face unexpected problems, as some also
indigenous populations in the Amazonian region may not accept
HBV vaccination for cultural reasons.
For hepatitis delta, areas of high prevalence include the
Mediterranean Basin, the Middle East, Central Asia, Amazon
Basin in South America and certain South Pacific islands [43].
Severe, often fatal, acute and chronic type D hepatitis occurs
among indigenous people for Venezuela, Colombia, Brazil and
Peru, all regions with high chronic HDV infection rates [44].
In Colombia, HDV infection is common in Amazonas and
Magdalena departments [37,38,45,46]. These data were con-
firmed in this study as the only anti-HDV positive samples found
were from these two departments: 8 (8,25%)/97 and 1 (2.5%)/40
among HBsAg and/or anti-HBc positive samples from Amazonas
and Magdalena departments, respectively. These two departments
have a huge jungle region and HDV genotype 3 predominates
[10,17]. Buitrago et al., in 1986, suggested that HDV infection has
been endemic in northern South America for more than 50 years.
The high frequency of HBV, together with the presence of HDV
markers, showed that these viruses represent the etiologic factors of
the ‘‘hepatitis of the Sierra Nevada de Santa Marta’’ [40]. It is
important to reinforce that a continuous surveillance of this area
allied to an intense HBV vaccination program is needed to control
this severe hepatic disease, as cases co-infected with both viruses
are still being detected.
The estimates of HCV prevalence in Colombia correspond to
data collected from blood donors, since there is no study of
prevalence in the general population [30]. A study reporting the
potential risk for an infectious disease through tainted transfusion
involving Colombian blood donors reported that 98.30% of them
were submitted to anti - HCV screening and 0.90% of those were
anti - HCV positive in 1993. This study also reported in Colombia
a probability of 74.55 per 10,000 donors of receiving an infected
transfusion and 67.09 per 10,000 donors of getting a transfusion-
transmitted infection, which was the highest risk of receiving a
blood unit infected with HCV and of contracting this infection in
Latin America [47]. Colombia has made screening for HCV
mandatory since 1993 [48] and the coverage for serology for that
infection in the blood banks has increased since now. In another
study, the screening coverage for anti-HCV in Colombia in 2002
increased to 99.70% and the risks of receiving an infected unit or
developing an infection after receiving an infected unit of blood in
decreased to 0.24 per 10,000 donors and 0.22 per 10,000 donors,
respectively [49]. These results strongly agree with previous results
from our group showing that HCV genotype 1b, the most frequent
in Colombia, exponentially spread up to 1992, when its growth
was controlled by HCV screening in Blood Banks [31].
In this study, anti - HCV frequency ranged from 0.66% in San
Andres Island up to 5.68% in Amazonas department. HCV is an
infection that probably arrived recently in Colombia [31] when
compared to HBV, which is found wide spread in Native
Colombians people and some HBV genotypes are quite probably
longer in South America [9]. Nevertheless, the widespread
presence of this infection throughout the world, the known
transmissions routes by blood supplies and other parenteral routes,
led this infection to spread around the world and it is present in all
the Colombians regions studied, in some of them in endemicity
levels that deserve deeper attention of health policy authorities.
In conclusion, HBV, HCV and HDV infections are detected
throughout Colombia in frequencies levels that would place some
areas as hyperendemic for HBV, especially those found in
Amazonas and Magdalena departments.
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